

MARK A. MINTUN, M.D.

CURRICULUM VITAE

May 2021

ADDRESS:

Office: Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly and Company)
3711 Market St
Philadelphia, PA 19104
Phone: 215-798-6022

PRESENT AND RECENT POSITIONS:

Vice-President of Alzheimer's Disease Development Unit
Eli Lilly and Company (2021 – present)

Vice-President of Pain and Neurodegeneration Research and Development
Eli Lilly and Company (2018 – present)

Vice-President of Pain Research and Clinical Development
Eli Lilly and Company (2017 – 2018)

President
Avid Radiopharmaceuticals (2014 - present)

Chief Medical Officer
Avid Radiopharmaceuticals (2010 – 2018)

Adjunct Professor of Radiology
University of Pennsylvania (2015 – present)

GOVERNMENT ADVISORY COMMITTEE SERVICE (Recent)

Member (Industry representative)
FDA Medical Imaging Drugs Advisory Committee (2019 - present)

EDUCATION:

Undergraduate:

1973-1977	Massachusetts Institute of Technology Cambridge, Massachusetts	B.S./1977	Chemical Engineering
-----------	---	-----------	----------------------

Graduate:

1977-1979	University of Kansas Kansas City, Kansas		Medicine
1979-1981	Washington University School of Medicine St. Louis, Missouri	M.D./1981	Medicine

POSTGRADUATE TRAINING:

- 1981-1982 Intern, Internal Medicine, Jewish Hospital of St. Louis, Missouri
- 1982-1984 Research Fellow, Neurology, Washington University School of Medicine, St. Louis, Missouri
- 1984-1985 Resident, Nuclear Medicine, Washington University School of Medicine, St. Louis, Missouri

ACADEMIC APPOINTMENTS:

- 1985-1989 Assistant Professor of Radiology, Washington University School of Medicine St. Louis, Missouri
- 1987-1989 Assistant Professor of Neurology (Joint), Washington University School of Medicine, St. Louis, Missouri
- 1989-1991 Associate Professor of Internal Medicine (Nuclear Medicine), University of Michigan Medical School, Michigan
- 1991-1996 Associate Professor of Radiology, University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania
- 1997-2000 Associate Professor of Radiology, Washington University School of Medicine, St. Louis, Missouri
- 2000-2010 Professor of Radiology, Washington University School of Medicine, St. Louis, Missouri
- 2015-current Adjunct Professor of Radiology, University of Pennsylvania, Philadelphia, PA

CLINICAL AND ADMINISTRATIVE APPOINTMENTS:

- 1985-1989 Assistant Radiologist, Barnes Hospital, St. Louis, Missouri
- 1985-1989 Consulting Radiologist, St. Louis Children's Hospital, St. Louis, Missouri
- 1989-1991 Consulting Nuclear Medicine Physician Staff, University of Michigan Hospital, Ann Arbor, Michigan
- 1991-1996 Staff Radiologist, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
- 1991-1996 Medical Director, PET Facility, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
- 1997-2010 Radiologist, St. Louis Children's Hospital, St. Louis, Missouri
- 1997-2010 Nuclear Medicine Radiologist, Barnes-Jewish Hospital, St. Louis, Missouri
- 1999-2010 Staff Radiologist, Barnes-Jewish West County Hospital, St. Louis, Missouri
- 2003-2010 Co-Director, Electronic Radiology Lab, Washington University School of Medicine, St. Louis, Missouri
- 2004-2010 Director, Center for Clinical Imaging Research Washington University School of Medicine, St. Louis, Missouri
- 2006-2010 Director, Division of Research Development, Department of Radiology, Washington University School of Medicine, St. Louis, Missouri
- 2007-2010 Interim Director, Division of Radiological Sciences, Department of Radiology, Washington University School of Medicine, St. Louis, Missouri
- 2009-2010 Vice Chair for Research, Department of Radiology, Washington University School of Medicine, St. Louis, Missouri

MEDICAL LICENSURE AND BOARD CERTIFICATION:

1982 National Board of Medical Examiners

Specialty Board:

1985 American Board of Nuclear Medicine

Medical License:

1982 Missouri No. R6C45 (inactive)

HONORS AND AWARDS:

1981 Hugh M. Wilson Award for Research in Radiology
1988 Research and Education Scholar of the Radiology Society of North America
1989 Tetalman Memorial Award of the Society of Nuclear Medicine
2006 Turken Award, UCLA and the Sam & Ida Turken Charitable Foundation

PUBLICATIONS

Peer-Reviewed Original Articles:

1. **Mintun MA**, Himmelstein KJ, Schroder RL, Gibaldi M, Shen DD: Tissue Distribution Kinetics of Tetraethylammonium Ion in the Rat. *J Pharmacokinet Biopharm* 1980; 8:373-409.
2. Smith MA, Schloerb PR, **Mintun MA**: Prediction of Total Exchangeable Body Sodium from the Early Tracer Disappearance Curve. *Curr Surg* 1980; 37(3):214-217.
3. Schloerb PR, Palaskas CL, **Mintun MA**: Rapid Computer Prediction of Total Water in Fluid Overload. *J Trauma* 1981; 21(9):757-761.
4. Mooney KG, **Mintun MA**, Himmelstein KJ, Stella VJ: Dissolution Kinetics of Carboxylic Acids I: Effect of pH under Unbuffered Conditions. *J Pharm Sci* 1981; 70:13-22.
5. Mooney KG, **Mintun MA**, Himmelstein KJ, Stella VJ: Dissolution Kinetics of Carboxylic Acids II: Effect of Buffers. *J Pharm Sci* 1981; 70:22-32.
6. Raichle ME, Martin WRW, Herscovitch P, **Mintun MA**, Markham J: Brain Blood Flow Measured with Intravenous H²¹⁵O II: Implementation and Validation. *J Nucl Med* 1983; 24(9):790-798.
7. Welch MJ, Kilbourn MR, Mathias CJ, **Mintun MA**, Raichle ME: Comparison in Animal Models of 18F-spiroperidol and 18F-haloperidol: Potential Agents for Imaging the Dopamine Receptor. *Life Sci* 1983; 33:1687-1693.

8. **Mintun MA**, Raichle ME, Martin WRW, Herscovitch P: Brain Oxygen Utilization Measured with O-15 Radiotracers and Positron Emission Tomography. *J Nucl Med* 1984; 25:177-187.
9. **Mintun MA**, Raichle ME, Kilbourn MR, Wooten FG, Welch MJ: A Quantitative Model for the In Vivo Assessment of Drug Binding Sites with Positron Emission Tomography. *Ann Neurol* 1984; 15:217-227.
10. Fox PT, **Mintun MA**, Herscovitch P, Raichle ME: A Noninvasive Approach to Quantitative Functional Brain Mapping with H215O and Positron Emission Tomography. *J Cereb Blood Flow Metab* 1984; 4:329-333.
11. Herscovitch P, **Mintun MA**, Raichle ME: Brain Oxygen Utilization Measured with Oxygen-15 Radiotracers and Positron Emission Tomography: Generation of Metabolic Images. *J Nucl Med* 1985; 26:416-417.
12. Powers WJ, Grubb RL, Baker RP, **Mintun MA**, Raichle ME: Regional Cerebral Blood Flow and Metabolism in Reversible Ischemia due to Vasospasm: Determination by Positron Emission Tomography. *J Neurosurg* 1985; 62:539-546.
13. Schuster DP, **Mintun MA**, Green MA, Ter-Pogossian MM: Regional Lung Water and Hematocrit Determined by Positron Emission Tomography. *J Appl Physiol* 1985; 59:860-868.
14. **Mintun MA**, Ter-Pogossian MM, Green MA, Lich LL, Schuster DP: Quantitative Measurement of Regional Pulmonary Blood Flow with Positron Emission Tomography. *J Appl Physiology* 1986; 60:317-326.
15. Schuster DP, Marklin GF, **Mintun MA**: Regional Changes in Extravascular Lung Water Detected by Positron Emission Tomography. *J Appl Physiol* 1986; 60:1170-1178.
16. Perlmutter JS, Larson KB, Raichle ME, Markham J, **Mintun MA**, Kilbourn MR, Welch MJ: Strategies for In-Vivo Measurement of Receptor Binding Using Positron Emission Tomography. *J Cereb Blood Flow Metab* 1986; 6:154-169.
17. Nussbaum GH, Babbs CF, **Mintun MA**: The Results of a Preliminary Study of Vasodilators for Improving Thermotherapy of Deep-Seated Tumors. *Int J Hyperthermia*, 1986; 2:61-64.
18. Schuster DP, Marklin GF, **Mintun MA**, Ter-Pogossian MM: PET Measurement of Regional Lung Density: 1. *J Comput Assist Tomogr* 1986; 10:723-729.
19. Fox PT, **Mintun MA**, Raichle ME, Meizen FM, Allman JM, VanEssen DC: Mapping Human Visual Cortex with Positron Emission Tomography. *Nature* 1986; 323:806-809.
20. **Mintun MA**, Dennis DR, Welch MJ, Mathias CJ, Schuster DP: Measurements of Pulmonary Vascular Permeability with Positron Emission Tomography and Ga-68 Transferrin. *J Nucl Med* 1987; 28:1704-1716.
21. Petersen SE, Fox PT, **Mintun MA**, Posner MI, Raichle ME: Positron emission tomographic studies of the cortical anatomy of single-word processing. *Nature* 1988; 331:585-589.

22. Fox PT, **Mintun MA**, Reiman EM, Raichle ME: Enhanced Detection of Focal Brain Responses Using Intersubject Averaging and Change-Distribution Analysis of Subtracted PET Images. *J Cereb Blood Flow Metab* 1988; 8:642-653.
23. Calandrino FS, Anderson DJ, **Mintun MA**, Schuster DJ: Pulmonary Vascular Permeability During the Adult Respiratory Distress Syndrome: A Positron Tomography Study. *Am Rev Respir Dis* 1988; 138:421-428.
24. **Mintun MA**, Welch MJ, Siegel BA, Mathias CJ, Brodack JA, McGuire AH, Katzenellenbogen JA: Breast Cancer: PET Imaging of Estrogen Receptors. *Radiology* 1988; 169:45-48.
25. Fox PT, Raichle ME, **Mintun MA**, Dence C: Nonoxidative Glucose Consumption during Focal Physiologic Neural Activity. *Science* 1988; 241:462-464.
26. Videen TO, Perlmutter JS, **Mintun MA**, Raichle ME: Regional Correction of Positron Emission Tomography Data for the Effects of Cerebral Atrophy. *J Cereb Blood Flow Metab* 1988; 8:662-670.
27. **Mintun MA**, Fox PT, Raichle ME: A Highly Accurate Method of Localizing Regions of Neuronal Activation in the Human Brain Using Positron Emission Tomography. *J Cereb Blood Flow Metab* 1989; 9:96-103.
28. Fox PT, **Mintun MA**: Noninvasive Functional Brain Mapping by Change-Distribution Analysis of Averaged PET Images of H₂¹⁵O Tissue Activity. *J Nucl Med* 1989; 30:141-149.
29. Reiman EM, Raichle ME, Robins E, **Mintun MA**, Fusselman MJ, Fox PT, Price JL, Hackman KA. Neuroanatomical Correlates of a Lactate-Induced Anxiety Attack. *Arch Gen Psychiatry* 1989; 46:493-500.
30. Petersen SE, Fox PT, Posner MI, **Mintun MA**, Raichle ME: Positron Emission Tomographic Studies of the Processing of Single Words. *J Cognit Neurosci* 1989; 1:153-170.
31. Mathias CJ, Welch MJ, Raichle ME, **Mintun MA**, Lich LL, McGuire AH, Zinn KR, John EK, Green MA: Evaluation of a Potential Generator-Produced PET Tracer for Cerebral Perfusion Imaging: Single-Pass Cerebral Extraction Measurements and Imaging with Radiolabeled Cu-PTSM. *J Nucl Med* 1990; 31:351-359.
32. **Mintun MA**, Warfel TE, Schuster DP: Evaluating Pulmonary Vascular Permeability with Radiolabeled Proteins: An Error Analysis. *J Appl Physiol* 1990; 68:1696-1706.
33. McGuire AH, Dehdashti F, Siegel B, Lyss A, Brodack J, Mathias C, **Mintun MA**, Katzenellenbogen JA, Welch MJ: Positron Tomographic Assessment of 16 α -[18F] Fluoro-17 β -Estradiol Uptake in Metastatic Breast Carcinoma. *J Nucl Med* 1991; 32:1526-1531.
34. Beanlands RSB, Muzik O, **Mintun MA**, Manger T, Lee K, Petry N, Hutchins GD, Schwaiger M: The Kinetics of Copper-62 PTSM in the Normal Human Heart. *J Nucl Med* 1992; 33(5):684-690.

35. Kuten A, Roval HD, Griffeth LK, **Mintun MA**, Perez, CA, Wasserman TH, Ter-Pogossian MM: Positron Emission Tomography in the Study of Acute Radiation Effects on Renal Blood Flow in Dogs. *Int Urol Nephrol* 1992; 24(5): 527-9.
36. Minoshima S, Berger K, **Mintun MA**: An Automated Method for Rotational Correction and Centering of Three Dimensional Functional Brain Images. *J Nucl Med* 1992; 33:(8)1579-1585.
37. Jonides J, Smith EE, Koeppe RA, Awh E, Minoshima S, **Mintun MA**: Spatial Working Memory in Humans as Revealed by PET. *Nature* 1993; 363:(6430)623-625.
38. Minoshima S, Koeppe RA, **Mintun MA**, Berger KL, Taylor SS, Frey KA and Kuhl DE. Automated Detection of the Intercommissural (AC-PC) Line for Stereotactic Localization of Functional Brain Images. *J Nucl Med* 1993; 34 :(2)322-329.
39. Quarles RP, **Mintun MA**, Larson KB, Markham J, MacLeod A, Raichle ME: Measurement of Regional Cerebral Blood Flow with Positron Emission Tomography: A Comparison of O-15-Water to C-11 Butanol with Distributed-Parameter and Compartmental Models. *J Cereb Blood Flow Metab* 1993;13:(5)733-747.
40. Diehl DJ, **Mintun MA**, Kupfer DJ and Moore RY: A Likely In Vivo Probe of Human Circadian Timing System Function Using PET. *Biological Psychiatry* 1994;36:562-565.
41. Becker JT, **Mintun MA**, Diehl DJ, Dobkin J, Martidis A, Madoff D and Dekosky ST: Functional Neuroanatomy of Verbal Free Recall: A Replication Study. *Human Brain Mapping* 1994;1:284-292.
42. Mathis CA, Simpson NR, Mahmood K, Kinahan PE, **Mintun MA**. [11C]WAY 100635: A Radioligand for Imaging 5-HT1A Receptors with Positron Emission Tomography. *Life Sciences (Pharmacology Letters)* 1994;55:PL403-407.
43. Reynolds III CF, Zubenko GS, Pollock BG, Mulsant BH, Schulz R, **Mintun MA**, Mazumdar S and Kupfer DJ. Depression in Late Life. *Curr Opin Psychiatry* 1994;7:18-21.
44. Ganguli R, **Mintun MA**, Becker JT, Brar JS, Diehl D, Deleo M, Madoff D, and Martidis A. Effects of Hydrocortisone Infusion on rCBF in Schizophrenic Patients during a Memory Task. An O-15 PET Study. *Ann NY Acad Sci* 1994; 746:385-387.
45. S. Dubé, **M.A. Mintun**, T.E. Nichols, P. Houck, D.M. Ojk, D.J. Kupfer, C.F. Reynolds III. Brain glucose uptake changes with total sleep deprivation (SD): — relationship to sleep and temperature. *Biol Psychiatry*, 1994; 35;9:663.
46. Forman SD, Cohen JD, Fitzgerald M, Eddy WF, **Mintun MA** and Noll DC. Improved Assessment of Significant Activation in Functional Magnetic Resonance Imaging (fMRI): Use of a Cluster-Size Threshold. *Magn Reson Med* 1995;33:636-647.
47. Carter CS, **Mintun MA**, and Cohen JD. Interference and Facilitation Effects During Selective Attention: An [15O]-H2O PET Study of Stroop Task Performance. *NeuroImage* 1995;2:264-272.

48. Becker JT, **Mintun MA**, Aleva K, Wiseman MB, Nichols T, and DeKosky ST. Compensatory Reallocation of Brain Resources Supporting Verbal Episodic Memory in Alzheimer's Disease. *Neurology* 1996;46:692-700 .
49. Sweeney JS, **Mintun MA**, Kwee S, Wiseman MB, Brown DL, Rosenberg D and Carl JR. Positron Emission Tomography Studies of Voluntary Saccadic Eye Movements and Spatial Working Memory. *J Neurophys* 1996;75:454-467.
50. Mann JJ, Malone KM, Diehl D, Perel J, Cooper TB and **Mintun MA**. Demonstration In Vivo of Reduced Serotonin Responsivity in the Brain of Untreated Depressed Patients. *Am J Psychiatry* 1996;153:174-182.
51. Mann JJ, Malone KM, Diehl DJ, Perel J, Nichols TE and **Mintun MA**. Positron Emission Tomographic Imaging of Serotonin Activation Effects on Prefrontal Cortex in Healthy Volunteers. *J Cereb Blood Flow Metab* 1996; 16:418-426.
52. Firestone L, Gyulai F, **Mintun MA**, Adler L, Urso K and Winter P. Human Brain Activity Response to Fentanyl Imaged by Positron Emission Tomography. *Anesth Analg* 1996;82:1247-1251.
53. Ganguli R, Carter CS, **Mintun MA**, Brar JS, Becker JT, Sarma R, Nichols T, and Bennington E. A PET Brain Mapping Study of Auditory Verbal Supraspan Memory versus Visual Fixation in Schizophrenia. *Biological Psychiatry* 1997; 41:33-42.
54. Gyulai FE, Firestone LL, **Mintun MA**, and Winter PM. In Vivo Imaging of Human Limbic Responses to Nitrous Oxide Inhalation. *Anesth Analg*, 1996;83(2):291-298.
55. Herbster AN, Nichols T, Wiseman MB, **Mintun MA**, DeKosky ST and Becker JT. Functional Connectivity in Auditory-Verbal Short-Term Memory in Alzheimer's disease. *Neuroimaging*, 1996; 4:67-77.
56. Kelly DE, **Mintun MA**, Watkins SC, Simoneau JA, Jalal F, Fredrickson A, Beattie J and Theriault R. The Effect of Non-insulin-dependent Diabetes Mellitus and Obesity on Glucose Transport and Phosphorylation in Skeletal Muscle. *J Clinical Investigation* 1996;97(12):2705-2713.
57. Adler LJ, Gyulai FE, Diehl DJ, **Mintun MA**, Firestone LL, and Winter PM. Regional Brain Activity Changes Associated with Fentanyl Analgesia Elucidated by Positron Emission Tomography. *Anesth Analg*, 1996; 84(1):120-126.
58. Gyulai F, Firestone LL, **Mintun MA** and Winter PM. In Vivo Imaging of Nitrous Oxide-induced Changes in Cerebral Activation during Noxious Heat Stimuli. *Anesthesiology*, 1997;86(3):538-548.
59. Herbster AN, **Mintun MA**, Nebes RD and Becker JT. Regional Cerebral Blood Flow during Word and Non-Word Reading. *Human Brain Mapping*, 1997; 5:84-92.
60. Berns GS, Cohen JD and **Mintun MA**. Brain Regions Responsive to Novelty in the Absence of Awareness. *Science*, 1997;276(5316):1272-1275

61. Carter CS, **Mintun MA**, Cohen JD and Nichols T. Anterior Cingulate Gyrus Dysfunction and Selective Attention Deficits in Schizophrenia: a 15-O-H₂O PET Study during Single Trial Stroop Task Performance. *Am J Psychiatry*, 1997; 154(12):1670-5.
62. Nofzinger EA, **Mintun MA**, Wiseman M, Kupfer DJ, and Moore RY. Forebrain Activation in REM sleep: an FDG PET Study. *Brain Research*, 1997; 770(1-2):192-201.
63. Nofzinger EA, **Mintun MA**, Price J, Meltzer CC, Townsend D, Buysse DJ, Reynolds CF 3rd, Datchile M, Matzzie J, Kupfer DJ, and Moore RY. A Method for the Assessment of the Functional Neuroanatomy of Human Sleep Using FDG PET. *Brain Research. Brain Research Protocols*, 1998;2(3):191-8
64. Zelkowitz BJ, Herbster BS, Nebes RD, **Mintun MA**, and Becker JT. An Examination of Regional Cerebral Blood Flow during Object Naming Tasks. *J Intrnl Neuropsychological Soc*, 1998, 4(2):160-6.
65. Jennings JR, Muldoon MF, Ryan CM, **Mintun MA**, Meltzer CC, Townsend DW, Sutton-Terrell K, Shapiro AP, and Manuck SB. Cerebral Blood Flow in Hypertensive Patients: An Initial Report of Reduced and Compensatory Blood Flow Responses during Performance of Two Cognitive Tasks. *Hypertension*, 1998;31:1216-1222.
66. Servan-Schreiber D, Perlstein WM, Cohen JD and **Mintun MA**. Selective Pharmacological Activation of Limbic Structures in Human Volunteers: A Positron Emission Tomography Study. *J Neuropsychiatry and Clin Neuroscience*, 1998; 10(2):148-159.
67. Carter CS, Perlstein W, Ganguli R, Brar J, **Mintun M**, and Cohen JD. Functional Hypofrontality and Working Memory Dysfunction in Schizophrenia. *Am J Psychiatry*, 1998; 155(9):1285-7
68. Sheline YI, Sanghavi M, **Mintun MA**, Gado MH. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. *Journal of Neuroscience*. 19(12):5034-43, 1999.
69. Ricci PT, Zelkowitz BJ, Nebes RD, Meltzer CC, **Mintun MA**, Becker JT. Functional neuroanatomy of semantic memory: recognition of semantic associations. *Neuroimage*. 9(1):88-96, 1999.
70. Meltzer CC, Smith G, Price JC, Reynolds CF III, Mathis CA, Greer P, Lopresti B, **Mintun MA**, Pollock BG, Ben-Eliezer D, Cantwell MN, Kaye W, DeKosky ST. Reduced binding of [18F]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction. *Brain Research*. 813(1):167-71, 1998.
71. Wiseman MB, Sanchez JA, Buechel C, **Mintun MA**, Lopez OL, Milko D, and Becker JT. Patterns of Relative Cerebral Blood Flow in Minor Cognitive Motor Disorder in Human Immunodeficiency Virus Infection. . *J Neuropsychiatry and Clin Neuroscience*, 1999;11:222-233.
72. Chao KS, Bosch WR, Mutic S, Lewis JS, Dehdashti F, **Mintun MA**, Dempsey JF, Perez CA, Purdy JA, Welch MJ. A novel approach to overcome hypoxic tumor resistance: Cu-

ATSM-guided intensity-modulated radiation therapy. *Int J Radiat Oncol Biol Phys* 2001 Mar 15; 49(4): 1171-1182.

73. **Mintun MA**, Lundstrom BN, Snyder AZ, Vlassenko AG, Shulman GL, Raichle ME. Blood Flow and Oxygen Delivery to Human Brain During Functional Activity: Theoretical Modeling and Experimental Data. *Proc Natl Acad Sci USA* 2001; 58:6859-6864.
74. Sheline YI, Barch DM, Donnelly JM, Ollinger JM, Snyder AZ, **Mintun MA**. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: An fMRI study. *Biol Psychiatry* 2001; 50(9):651-658.
75. Gyulai FE, **Mintun MA**, Firestone LL. Dose-dependent enhancement of in vivo GABA_A/BDZ receptor binding by isoflurane. *Anesthesiology* 2001; Sep95 (3): 585-593.
76. Sheline YI, Snyder AZ, Moerlein SM, **Mintun MA**. Loss of 5-HT_{2A} receptors may occur primarily in mid-life. *Am J Psychiatry* 2002; 159(3):430-435.
77. Ganguli, R, Singh A, Brar J, Carter C, **Mintun M**. Hydrocortisone induced regional cerebral activity changes in schizophrenia: a PET scan study. *Schizophr. Res.* 2002 Aug 1; 56(3): 241-7.
78. **Mintun MA**, Vlassenko AG, Shulman GL, Snyder AZ. Time-related increase of oxygen utilization in continuously activated human visual cortex. *NeuroImage* 2002; 16(2): 531-37.
79. Sheline YI, Mittler BL, **Mintun MA**. The hippocampus and depression. *Eur Psychiatry* 2002; 17 Suppl 3:300-5.
80. Logan TF, Jadali F, Egorin MJ, **Mintun MA**, Sashin D, Gooding WE, Choi Y, Bishop H, Trump DL, Gardner D, Kirkwood J, Vlock D, Johnson C. Decreased tumor blood flow as measured by positron emission tomography in cancer patients treated with interleukin-1 and carboplatin on a phase 1 trial. *Cancer Chemother Pharmacol* 2002; 50:433-44
81. Dehdashti F, Grigsby PW, **Mintun MA**, Lewis JS, Siegel BA, Welch MJ: Assessing tumor hypoxia in cervical cancer by positron emission tomography with ⁶⁰Cu-ASTM: Relationship to therapeutic response—A Preliminary report. *Int J Radiat Oncol Biol Phys* 2003; 55:1233-38.
82. Black KJ, Hershey T, Koller JM, Videen TO, **Mintun MA**, Price JL, Perlmutter JS: A possible substrate for dopamine-related changes in mood and behavior: Prefrontal and limbic effects of a D3-preferring dopamine agonist. *PNAS* 2002; 99: 17113-17118
83. Dehdashti F, **Mintun MA**, Lewis JS, Bradley J, Govindan R, Lafortest R, Welch MJ, Siegel BA. In vivo assessment of tumor hypoxia in lung cancer with ⁶⁰Cu-ASTM. *Eur J Nuc Med* 2003 Apr 13.
84. Lee BC, **Mintun MA**, Buckner RL, Morris JC. Imaging of Alzheimer's disease. *J Neuroimaging*; 2003;13(3):199-214.
85. **Mintun M**, Vlassenko A, Rundle M, Raichle M. Increased lactate/pyruvate ratio augments blood flow in physiologically activated human brain. *PNAS* 2004; 101:659-64.

86. **Mintun MA.**, Sheline YI., Moerlien SM., Vlassenko AG., Huang Y., Snyder A. Decreased hippocampal 5-HT_{2A} receptor binding in major depressive disorder: In vivo measurement with [18F] altanserin positron emission tomography. *Biological Psychiatry* 2004 Feb 1; 55(3):217-24.
87. Richard J.C., Zhou Z., Chen D.L., **Mintun M.A.**, Piwnica-Worms D, Factor P, Ponde, D.E., & Schuster, D.P. Quantitation of pulmonary transgene expression with PET imaging. *J Nucl Med* 2004; 45 644-654
88. Chen, D.L., **Mintun, M.A.**, Schuster, D.P. A comparison of methods to quantitate ¹⁸F-fluorodeoxyglucose uptake with positron emission tomography during experimental acute lung injury. *J Nuc Med* 2004; 45(9):1583-90.
89. Vlassenko AG, Sheline YI, Fischer K, **Mintun MA**. Cerebral perfusion response to successful treatment of depression with different serotonergic agents. *J Neuropsychiatry and Clinical Neurosciences* 2004; 16:360-63.
90. Sheline YI, **Mintun MA**, Barch DM, Wilkins C, Snyder AZ, Moerlein SM. Decreased hippocampal 5-HT_{2A} receptor binding in late life depression using [18F]altanserin positron emission tomography. *Neuropsychopharm*, 2004; 29(12):2235-2241.
91. Bradley JD. Dehdashti F. **Mintun MA**. Govindan R. Trinkaus K. Siegel BA. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. *Journal of Clinical Oncology.*, 2004; 22(16):3248-54.
92. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, **Mintun MA**. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. *J Neurosci*. 2005; 25(34):7709-17.
93. Chen DL, Ferkol TW, **Mintun MA**, Pittman JE, Rosenbluth DB, Schuster DP. Quantifying pulmonary inflammation in cystic fibrosis with positron emission tomography. *Am J Respir Crit Care Med* 2006; 173 (12); 1363-9.
94. Mathews J, Garcia KS, **Mintun MA**, Sheline YI. Antidepressant efficacy of olanzapine as monotherapy in major depressive disorder, without psychosis: a pilot study. *Psychiatry Res*. 2006 March 31;146(2):149-55.
95. Conway CR, Sheline YI, Chibnall JT, George MS, Fletcher JW, **Mintun MA**. Cerebral blood flow changes during vagus nerve stimulation for depression. *Psychiatry Res* 2006; 146 (2):179-184.
96. Vlassenko AG, Rundle MM, Raichle ME, **Mintun MA**. Regulation of blood flow in activated human brain by cytosolic NADH/NAD⁺ ratio. *PNAS* 2006:103 (6):1964-1969.
97. Chen DL, Rosenbluth DB, **Mintun MA**, Schuster DP. FDG-PET Imaging of pulmonary inflammation in healthy volunteers after airway instillation of endotoxin. *J Appl. Physiol* 2006 May;100(5) 1602-9.
98. Fagan AM, **Mintun MA**, Mach RH, Lee S-Y, Dence CS, Shah AR, LaRossa G, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM (2005) Inverse

relationship between in vivo amyloid imaging load and CSF A β 42 in humans. *Annals of Neurology* 2006; 59:512-519.

99. **Mintun MA**, LaRossa GN, Sheline YI, Dence CS, Yoon Lee S, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC 2006 [^{11}C] PIB in a Nondemented Population: Potential Antecedent Marker of Alzheimer Disease. *Neurology* 2006; 67:446-452.
100. Raichle ME, **Mintun MA**: Brain Work and Brain Imaging. *Annu Rev Neurosci* 2006; 29:449-476.
101. Vlassenko AG, Rundle MM, **Mintun MA**. Human Brain Glucose Metabolism May Evolve During Activation: Findings From a Modified FDG PET Paradigm. *NeuroImage* 2006; 33: 1036-1041.
102. Fagan AM, Roe CM, Xiong C, **Mintun MA**, Morris JC, Holtzman DM. Cerebrospinal Fluid tau/A β 42 Predicts Cognitive Decline in Nondemented Older Adults. *Arch Neurol*. 2007 Mar;64(3):343-9. Epub 2007 Jan 8.
103. Innis RB, Cunningham VJ, Delforge, J, Fujita Masahiro, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Maguire RP, **Mintun MA**, Morris ED, Parsey R, Slifstein M, Sossi Vesna, Suhara Tetsuya, Votaw J, Wong DF. Consensus Nomenclature for Binding Potential and Related Terms Used in Radiology Imaging. *JCBF&M* 2007; Sept; 27(9):1533-9. Epub 2007 May 9.
104. Fales CL, Barch DM, Rundle MM, **Mintun MA**, Snyder AZ, Cohen JD, Mathews J, Sheline YI. Altered Emotional Interference Processing in Affective and Cognitive-Control Brain Circuitry in Major Depression. *Biol Psychiatry*. 2007 Aug 23, Epub ahead of print
105. Fotenos AF, **Mintun MA**, Synder AZ, Morris JC, Buchner RL. Brain Volume Decline in Aging: Evidence for a Relationship between SES, Preclinical AD and Reserve. *Arch Neurol*, Vol 65 (No. 1), Jan 2008.
106. Sheline YI, Vaishnavi SN, **Mintun MA**, Price JL, Wilkins CH, Synder AZ, Barch DM, Couture L, McKinstry RC. Regional WHM Burden in Automated Segmentation Distinguishes Late Life Depressed Subjects from Controls Matched for Vascular Risk Factors. *Am Journal of Psychiatry*, 2008 Apr; 165(4):524-32. Epub 2008 Feb 15.
107. Fales, CL, Barch DM, Rundle MM, **Mintun MA**, Mathews J, Snyder AZ, Sheline, YI. Antidepressant Treatment Normalizes Hypoactivity in Dorsolateral Prefrontal Cortex During Emotional Interference Processing in Major Depression. *J Affect Disord*, 2008 June. Epub ahead of print.
108. Roe CM, **Mintun MA**, D'Angelo G, Xiong C, Grant EA, Morris JC. Alzheimer's and Cognitive Reserve: Education Effect Varies with [^{11}C]PIB Uptake. *Arch Neurol*, 2008 65:1467-1471.
109. Sheline YI, Barch DM, Price JL, Rundle MM, Vaishnavi SN, Snyder AZ, **Mintun MA**, Wang S, Coalson RS, Raichle ME. The Default Mode Network and Self-Referential Processes in Depression. *PNAS* 2009 Feb;106(6):1942-7. Epub 2009 Jan 26.

110. Fagan AM, Head D, Shah AR, Marcus D, **Mintun MA**, Morris JC, Holtzman DM. Decreased Cerebrospinal Fluid A β ₄₂ Correlates with Brain Atrophy in Cognitively Normal Elderly. *Ann Neurol* 2009 65(2):176-183. PMID: PMC2763631
111. Shimony JS, Sheline YI, D'Angelo G, Epstein AA, Benzinger, TL, **Mintun, MA**, McKinstry RC, Snyder AZ. Diffuse Microstructural Abnormalities of Normal Appearing White Matter in Late Life Depression: A Diffusion Tensor Imaging Study. *Biol Psychiatry*. 2009 Aug 1;66(3):245-52. Epub 2009 Apr 17. PMID: PMC2804471
112. Xu J, Chu W, Tu Z, Jones LA, Luedtke RR, Perlmutter JS, **Mintun MA**, Mach RH. [(3)H]4-(Dimethylamino)-N-[4-(4-(2-methoxyphenyl)piperazin- 1-yl)butyl]benzamide, a selective radioligand for dopamine D(3) receptors. I. In vitro characterization. *Synapse*. 2009 Sep;63(9):717-28. PMID: PMC2783604
113. Storandt M, **Mintun MA**, Head D, Morris JC. Cognitive decline and brain volume loss are signatures of cerebral A β depositions identified with PIB. *Arch Neurol*. 2009 Dec;66(12):1476-81. PMID: PMC2796577
114. Chen D, Bedient T, Kozlowski J, Rosenbluth D, Isakow W, Ferkol T, Thomas B, **Mintun M**, Schuster D, Walter M. [18F]fluorodeoxyglucose positron emission tomography for lung anti-inflammatory response evaluation. *Am J Respir Crit Care Med*. 2009 Sep 15;180(6):533-9. Epub 2009 Jul 2. PMID: PMC2742744
115. Hinrichs AL, **Mintun MA**, Head D, Fagan AM, Holtzman DM, Morris JC, Goate AM. Cortical Binding of Pittsburgh Compound B and Endophenotype for Genetic Studies of Alzheimer's disease. *Biol Psychiatry* 2010 Mar 15; 67(6):581-3. Epub 2009 Nov 5.
116. Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, **Mintun MA**. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. *Arch Neurol*. 2009 Dec;66(12):1469-75. PMID: PMC2798814
117. Fagan AM, **Mintun MA**, Shah AR, Aldea P, Roe CM, Mach RH, Marcus D, Morris JC, Holtzman DM. Cerebrospinal fluid tau and ptau₁₈₁ increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease. *EMBO Mol Med*. 2009 Nov;1(8-9):371-80. PMID: PMC2806678
118. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, **Mintun MA**. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. *Ann Neurol*. 2010 Jan;67(1):122-31.
119. Sheline YI, Raichle ME, Snyder AZ, Morris JC, Head D, Wang S, **Mintun MA**. Amyloid Plaques Disrupt Resting State Default Mode Network Connectivity in Cognitively Normal Elderly. *Biol Psychiatry*. 2010 Mar 15;67(6):584-7. Epub 2009 Oct 14.
120. Cairns N, Ikonovic M, Benzinger T, Storandt M, Fagan A, Shah A, Reinwald L, Carter D, Felton A, Holtzman D, **Mintun M**, Klunk W, Morris JC. Absence of PIB detection of cerebral A β in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. *Arch Neurol*. 2009 Dec; 66(12):1557-62.

121. Benzinger TL, Brody D, Cardin S, Curley KC, **Mintun MA**, Mun SK, Wong KH, Wrathall JR. Blast-related Brain Injury: Imaging for Clinical and Research Applications Report of the 2008 St. Louis Workshop. *J Neurotrauma*. 2009 Dec;26(12):2127-44. PMID: PMC2824226
122. Galvin JE, Fagan AM, Holtzman DM, **Mintun MA**, Morris JC. Relationship of dementia screening tests with biomarkers of Alzheimer's disease. *Brain*. 2010 Nov;133(11):3290-300.
123. Liang KY, **Mintun MA**, Fagan AM, Goate AM, Bugg JM, Holtzman DM, Morris JC, Head D. Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. *Ann Neurol*. 2010 Sep;68(3):311-8.
124. Zeng C, Pan F, Jones LA, Lim MM, Griffin EA, Sheline YI, **Mintun MA**, Holtzman DM, Mach RH. Evaluation of 5-ethynyl-2'-deoxyuridine staining as a sensitive and reliable method for studying cell proliferation in the adult nervous system. *Brain Res*. 2010 Mar 10;1319:21-32. Epub 2010 Jan 11. PMID: PMC2826567.
125. Ances BM, Christensen JJ, Teshome M, Taylor J, Xiong C, Aldea P, Fagan AM, Holtzman DM, Morris JC, **Mintun MA**, Clifford DB. Cognitively Unimpaired HIV+ Participants Do Not Have Increased 11C-PiB: A Case Control Study. *Neurology*. 2010. Jul 13;75(2):111-5.
126. Roe CM, **Mintun MA**, Ghoshal N, Williams MM, Grant EA, Marcus DS, Morris JC. Alzheimer disease identification using amyloid imaging and reserve variables: proof of concept. *Neurology*. 2010 Jul 6;75(1):42-8.
127. Sheline YI, Price JL, Yan Z, **Mintun MA**. Resting-state functional MRI in depression unmasks increased connectivity between networks via the dorsal nexus. *Proc Natl Acad Sci U S A*. 2010 Jun 15;107(24):11020-5. Epub 2010 Jun 1.
128. Vaishnavi SN, Vlassenko AG, Rundle MM, Snyder AZ, **Mintun MA**, Raichle ME. Regional aerobic glycolysis in the human brain. *Proc Natl Acad Sci USA*. 2010 Nov 15;68(10):903-12.
129. Vlassenko AG, Vaishnavi SN, Couture L, Sacco D, Shannon BJ, Mach RH, Morris JC, Raichle ME, **Mintun MA**. Spatial correlation between brain aerobic glycolysis and amyloid- β ($A\beta$) deposition. *Proc Natl Acad Sci USA*. 2010 Oct 12;107(41):17763-7.
130. Xu J, Hassanzadeh B, Chu W, Tu Z, Jones LA, Luedtke RR, Perlmutter JS, **Mintun MA**, Mach RH. [3H]4-(dimethylamino)-N-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)benzamide: a selective radioligand for dopamine D(3) receptors. II. Quantitative analysis of dopamine D(3) and D(2) receptor density ratio in the caudate-putamen. *Synapse*. 2010 Jun;64(6):449-59.
131. Sheline YI, Morris JC, Snyder AZ, Price JL, Yan Z, D'Angelo G, Liu C, Dixit S, Benzinger T, Fagan A, Goate A, **Mintun MA**. APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF A β 42. *J Neurosci*. 2010 Dec 15;30(50):17035-40.

132. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, **Mintun MA**, Pontecorvo MJ, Hefti F, Carpenter AP, Flitter ML, Krautkramer MJ, Kung HF, Coleman RE, Doraiswamy PM, Fleisher AS, Sabbagh MN, Sadowsky CH, Reiman EP, Zehntner SP, Skovronsky DM; AV45-A07 Study Group. Use of florbetapir-PET for imaging beta-amyloid pathology. *JAMA*. 2011 Jan 19;305(3):275-83.
133. Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, **Mintun MA**, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D'Angelo G, Malone JP, Townsend RR, Morris JC, Fagan AM, Holtzman DM. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. *Biol Psychiatry*. 2010 Nov 15;68(10):903-12.
134. Fagan AM, Shaw LM, Xiong C, Vanderstichele H, **Mintun MA**, Trojanowski JQ, Coart E, Morris JC, Holtzman DM. Comparison of Analytical Platforms for Cerebrospinal Fluid Measures of {beta}-Amyloid 1-42, Total tau, and P-tau181 for Identifying Alzheimer Disease Amyloid Plaque Pathology. *Arch Neurol*. 2011 Sep;68(9):1137-44.
135. Fleisher AS, Chen K, Liu X, Rontiva A, Thiyyagura P, Ayutyanont N, Joshi AD, Clark CM, **Mintun MA**, Pontecorvo MJ, Doraiswamy PM, Johnson KA, Skovronsky DM, Reiman EM. Using positron emission tomography and Florbetapir F 18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer Disease. *Arch Neurol*. 2011. Nov;68(11):1404-11. Epub 2011 Jul 11.
136. Lister-James J, Pontecorvo MJ, Clark C, Joshi AD, **Mintun MA**, Zhang W, Lim N, Zhuang Z, Golding G, Choi SR, Benedum TE, Kennedy P, Hefti F, Carpenter AP, Kung HF, Skovronsky DM. Florbetapir F-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent. *Semin Nucl Med*. 2011 Jul;41(4):300-4.
137. Mach RH, Tu Z, Xu J, Li S, Jones LA, Taylor M, Luedtke RR, Derdeyn CP, Perlmutter JS, **Mintun MA**. Endogenous dopamine (DA) competes with the binding of a radiolabeled D₃ receptor partial agonist in vivo: a positron emission tomography study. *Synapse*. 2011 Aug;65(8):724-32.
138. Pontecorvo MJ, **Mintun MA**. PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease. *Alzheimer's Res Ther*. 2011 Mar 29;3(2):11.
139. Roe CM, Fagan AM, Williams MM, Ghoshal N, Aeschleman M, Grant EA, Marcus DS, **Mintun MA**, Holtzman DM, Morris JC. Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease. *Neurology*. 2011 Feb 8;76(6):501-10.
140. Piccirillo JF, Garcia KS, Nicklaus J, Pierce K, Burton H, Vlassenko AG, **Mintun M**, Duddy D, Kallogjeri D, Spitznagel EL Jr. Low-frequency repetitive transcranial magnetic stimulation to the temporoparietal junction for tinnitus. *Arch Otolaryngol Head Neck Surg*. 2011 Mar;137(3):221-8.
141. Tarawneh R, D'Angelo G, Macy E, Xiong C, Carter D, Cairns NJ, Fagan AM, Head D, **Mintun MA**, Ladenson JH, Lee JM, Morris JC, Holtzman DM. Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. *Ann Neurol*. 2011 Aug;70(2):274-85.

142. Roe CM, Fagan AM, Grant EA, Marcus DS, Benzinger TL, **Mintun MA**, Holtzman DM, Morris JC. Cerebrospinal fluid biomarkers, education, brain volume, and future cognition. *Arch Neurol*. 2011 Sep;68(9):1145-51.
143. Cirrito JR, Disabato BM, Restivo JL, Verges DK, Goebel WD, Sathyan A, Hayreh D, D'Angelo G, Benzinger T, Yoon H, Kim J, Morris JC, **Mintun MA**, Sheline YI. Serotonin signaling is associated with lower amyloid- β levels and plaques in transgenic mice and humans. *Proc Natl Acad Sci U S A*. 2011 Sep 6;108(36):14968-73. Epub 2011 Aug 22.
144. Xiong C, Roe CM, Buckles V, Fagan A, Holtzman D, Balota D, Duchek J, Storandt M, **Mintun M**, Grant E, Snyder AZ, Head D, Benzinger TL, Mettenburg J, Csernansky J, Morris JC. Role of family history for Alzheimer biomarker abnormalities in the adult children study. *Arch Neurol*. 2011 Oct;68(10):1313-9.
145. Sabbagh MN, Fleisher A, Chen K, Rogers J, Berk C, Reiman E, Pontecorvo M, **Mintun M**, Skovronsky D, Jacobson SA, Sue LI, Liebsack C, Charney AS, Cole L, Belden C, Beach TG. Positron emission tomography and neuropathologic estimates of fibrillar amyloid- β in a patient with Down syndrome and Alzheimer disease. *Arch Neurol*. 2011 Nov;68(11):1461-6.
146. Vlassenko AG, **Mintun MA**, Xiong C, Sheline YI, Goate AM, Benzinger TL, Morris JC. Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. *Ann Neurol*. 2011 Nov;70(5):857-61.
147. Zha Z, Choi SR, Ploessl K, Lieberman BP, Qu W, Hefti F, **Mintun M**, Skovronsky D, Kung HF. Multidentate (18)F-polypegylated styrylpyridines as imaging agents for A β plaques in cerebral amyloid angiopathy (CAA). *J Med Chem*. 2011 Dec 8;54(23):8085-98. Epub 2011 Nov 9.
148. Huang Y, Potter R, Sigurdson W, Santacruz A, Shih S, Ju YE, Kasten T, Morris JC, **Mintun M**, Duntley S, Bateman RJ. Effects of age and amyloid deposition on A β dynamics in the human central nervous system. *Arch Neurol*. 2012 Sep 10:1-7.
149. Head D, Bugg JM, Goate AM, Fagan AM, **Mintun MA**, Benzinger T, Holtzman DM, Morris JC. Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition. *Arch Neurol*. 2012 Jan 9.
150. Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, Adler LP, Kovnat KD, Seibyl JP, Arora A, Saha K, Burns JD, Lowrey MJ, **Mintun MA**, Skovronsky DM; Florbetapir F 18 Study Investigators. Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects. *J Nucl Med*. 2012 Mar;53(3):378-84. Epub 2012 Feb 13.
151. Bakken TE...**Mintun MA**...Carlson H. Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. *Proc Natl Acad Sci U S A*. 2012 Mar 6;109(10):3985-90. Epub 2012 Feb 16.
152. Vellas B, Hampel H, Rougé-Bugat ME, Grundman M, Andrieu S, Abu-Shakra S, Bateman R, Berman R, Black R, Carrillo M, Donohue M, **Mintun M**, Morris J, Petersen R, Thomas RG, Suhy J, Schneider L, Seely L, Tariot P, Touchon J, Weiner M, Sampaio

C, Aisen P; Task Force Participants. Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology. *J Nutr Health Aging*. 2012 Apr;16(4):339-45.

153. Conway CR, Sheline YI, Chibnall JT, Bucholz RD, Price JL, Gangwani S, **Mintun MA**. Brain blood-flow change with acute vagus nerve stimulation in treatment-refractory major depressive disorder. *Brain Stimul*. 2012 Apr;5(2):163-71. Epub 2011 Apr 3.
154. Fleisher AS, Chen K, Liu X, Ayutyanont N, Roontiva A, Thiyyagura P, Protas H, Joshi AD, Sabbagh M, Sadowsky CH, Sperling RA, Clark CM, **Mintun MA**, Pontecorvo MJ, Coleman RE, Doraiswamy PM, Johnson KA, Carpenter AP, Skovronsky DM, Reiman EM. Apolipoprotein E ϵ 4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. *Neurobiol Aging*. 2013 Jan;34(1):1-12.
155. Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, Grundman M, Sabbagh MN, Sadowsky CH, Fleisher AS, Carpenter A, Clark CM, Joshi AD, **Mintun MA**, Skovronsky DM, Pontecorvo MJ; For the AV45-A11 Study Group. Amyloid- β assessed by florbetapir F 18 PET and 18-month cognitive decline: A multicenter study. *Neurology*. 2012 Oct 16;79(16):1636-44
156. Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, Fleisher AS, Reiman EM, Sabbagh MN, Sadowsky CH, Schneider JA, Arora A, Carpenter AP, Flitter ML, Joshi AD, Krautkramer MJ, Lu M, **Mintun MA**, Skovronsky DM; for the AV-45-A16 Study Group. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid- β plaques: a prospective cohort study. *Lancet Neurol*. 2012 Aug;11(8):669-678. Epub 2012 Jun 28.
157. Conway CR, Chibnall JT, Gangwani S, **Mintun MA**, Price JL, Hershey T, Giuffra LA, Bucholz RD, Christensen JJ, Sheline YI. Pretreatment cerebral metabolic activity correlates with antidepressant efficacy of vagus nerve stimulation in treatment-resistant major depression: A potential marker for response? *J Affect Disord*. 2012 Aug;139(3):283-90. Epub 2012 Mar 5.
158. Landau SM, **Mintun MA**, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, Weiner MW, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. *Ann Neurol*. 2012 Oct;72(4):578-86.
159. Huang Y, Potter R, Sigurdson W, Kasten T, Connors R, Morris JC, Benzinger T, **Mintun M**, Ashwood T, Ferm M, Budd SL, Bateman RJ. β -Amyloid Dynamics in Human Plasma. *Arch Neurol*. 2012 Dec 1;69(12):1591-7.
160. Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, **Mintun MA**. Amyloid- β imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods. *J Nucl Med*. 2013 Jan;54(1):70-7.
161. Su Y, Arbelaez AM, Benzinger TL, Snyder AZ, Vlassenko AG, **Mintun MA**, Raichle ME. Noninvasive estimation of the arterial input function in positron emission tomography imaging of cerebral blood flow. *J Cereb Blood Flow Metab*. 2013 Jan;33(1):115-21.

162. Grundman M, Pontecorvo MJ, Salloway SP, Doraiswamy PM, Fleisher AS, Sadowsky CH, Nair AK, Siderowf A, Lu M, Arora AK, Agbulos A, Flitter ML, Krautkramer MJ, Sarsour K, Skovronsky DM, **Mintun MA**; for the AV45-A17 Study Group. Potential Impact of Amyloid Imaging on Diagnosis and Intended Management in Patients With Progressive Cognitive Decline. *Alzheimer Dis Assoc Disord*. 2013 Jan 14.
163. Johnson KA, Sperling RA, Gidyczin CM, Carmasin JS, Maye JE, Coleman RE, Reiman EM, Sabbagh MN, Sadowsky CH, Fleisher AS, Murali Doraiswamy P, Carpenter AP, Clark CM, Joshi AD, Lu M, Grundman M, **Mintun MA**, Pontecorvo MJ, Skovronsky DM; AV45-A11 study group. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. *Alzheimers Dement*. 2013 Oct;9(5):S72-83.
164. Landau SM, Lu M, Joshi AD, Pontecorvo M, **Mintun MA**, Trojanowski JQ, Shaw LM, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative. Comparing PET imaging and CSF measurements of A β . *Ann Neurol*. 2013 Mar 28.
165. Sperling RA, Johnson KA, Doraiswamy PM, Reiman EM, Fleisher AS, Sabbagh MN, Sadowsky CH, Carpenter A, Davis MD, Lu M, Flitter M, Joshi AD, Clark CM, Grundman M, **Mintun MA**, Skovronsky DM, Pontecorvo MJ; AV45-A05 Study Group. Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. *Neurobiol Aging*. 2013 Mar;34(3):822-31.
166. Roe CM, Fagan AM, Grant EA, Hassenstab J, Moulder KL, Maue Dreyfus D, Sutphen CL, Benzinger TL, **Mintun MA**, Holtzman DM, Morris JC. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. *Neurology*. 2013 May 7;80(19):1784-91.
167. Su Y, D'Angelo GM, Vlassenko AG, Zhou G, Snyder AZ, Marcus DS, Blazey TM, Christensen JJ, Vora S, Morris JC, **Mintun MA**, Benzinger TL. Quantitative analysis of PiB-PET with FreeSurfer ROIs. *PLoS One*. 2013 Nov 6;8(11):e73377.
168. Conway CR, Chibnall JT, Gebara MA, Price JL, Snyder AZ, **Mintun MA**, Craig AD, Cornell ME, Perantie DC, Giuffra LA, Bucholz RD, Sheline YI. Association of cerebral metabolic activity changes with vagus nerve stimulation antidepressant response in treatment-resistant depression. *Brain Stimul*. 2013 Sep;6(5):788-97.
169. Dugger BN, Clark CM, Serrano G, Mariner M, Bedell BJ, Coleman RE, Doraiswamy PM, Lu M, Fleisher AS, Reiman EM, Sabbagh MN, Sadowsky CH, Schneider JA, Zehntner SP, Carpenter AP, Joshi AD, **Mintun MA**, Pontecorvo MJ, Skovronsky DM, Sue LI, Beach TG. Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates. *J Neuropathol Exp Neurol*. 2014 Jan;73(1):72-80.
170. Joshi AD, Pontecorvo MJ, Adler L, Stabin MG, Skovronsky DM, Carpenter AP, **Mintun MA**; Florbetapir F 18 study investigators. Radiation dosimetry of florbetapir F 18. *EJNMMI Res*. 2014 Jan 8;4(1):4.
171. Conway CR, Chibnall JT, Cumming P, **Mintun MA**, Gebara MA, Perantie DC, Price JL, Cornell ME, McConathy JE, Gangwani S, Sheline YI. Antidepressant response to

aripiprazole augmentation associated with enhanced FDOPA utilization in striatum: A preliminary PET study. *Psychiatry Res.* 2014 Mar 30;221(3):231-9.

172. Serrano GE, Sabbagh MN, Sue LI, Hidalgo JA, Schneider JA, Bedell BJ, VanDeerlin VM, Suh E, Akiyama H, Joshi AD, Pontecorvo MJ, **Mintun MA**, Beach TG. Positive Florbetapir PET Amyloid Imaging in a Subject with Frequent Cortical Neuritic Plaques and Frontotemporal Lobar Degeneration with TDP43-Positive Inclusions. *J Alzheimer's Dis.* 2014 Jan 1; 42(3):813-21.
173. Siderowf A, Pontecorvo MJ, Shill HA, **Mintun MA**, Arora A, Joshi AD, Lu M, Adler CH, Galasko D, Liebsack C, Skovronsky DM, Sabbagh MN. PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133(florbenazine) in patients with Alzheimer's disease and Lewy body disorders. *BMC Neurol.* 2014 Apr 9; 14:79.
174. Doraiswamy PM, Sperling RA, Johnson K, Reiman EM, Wong TZ, Sabbagh MN, Sadowsky CH, Fleisher AS, Carpenter A, Joshi AD, Lu M, Grundman M, **Mintun MA**, Skovronsky DM, Pontecorvo MJ; AV45-A11 Study Group.; Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. AV45-A11 Study Group. *Mol Psychiatry.* 2014 Sep;19(9):1044-51.
175. Landau SM, Thomas BA, Thurfjell L, Schmidt M, Margolin R, **Mintun M**, Pontecorvo M, Baker SL, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative. Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers. *Eur J Nucl Med Mol Imaging.* 2014 Jul;41(7):1398-407.
176. Hecimovic H, Santos J, Price JL, Sheline YI, **Mintun MA**, Snyder AZ, Christensen JJ, Carter J, Vahle V, Gilliam FG. Severe hippocampal atrophy is not associated with depression in temporal lobe epilepsy. *Epilepsy Behav.* 2014 May;34:9-14.
177. Sheline YI, West T, Yarasheski K, Swarm R, Jasielec MS, Fisher JR, Ficker WD, Yan P, Xiong C, Frederiksen C, Grzelak MV, Chott R, Bateman RJ, Morris JC, **Mintun MA**, Lee JM, Cirrito JR. An antidepressant decreases CSF A β production in healthy individuals and in transgenic AD mice. *Sci Transl Med.* 2014 May 14;6(236):236re4.
178. Chu W, Chepetan A, Zhou D, Shoghi KI, Xu J, Dugan LL, Gropler RJ, **Mintun MA**, Mach RH. Development of a PET radiotracer for non-invasive imaging of the reactive oxygen species, superoxide, in vivo. *Org Biomol Chem.* 2014 Jul 7;12(25):4421-31.
179. Tateno A, Sakayori T, Kawashima Y, Higuchi M, Suhara T, Mizumura S, **Mintun MA**, Skovronsky DM, Honjo K, Ishihara K, Kumita S, Suzuki H, Okubo Y. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [(18)F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy. *Int J Geriatr Psychiatry.* 2014 Jul 7.
180. Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, Johnson KA, Mathis CA, Minhas D, Pontecorvo MJ, Rowe CC, Skovronsky DM, **Mintun MA**. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. *Alzheimers Dement.* 2015 Jan;11(1):1-15.e1-4.

181. Hutton C, Declerck J, **Mintun MA**, Pontecorvo MJ, Devous MD Sr, Joshi AD; ADNI. Quantification of 18F-florbetapir PET: comparison of two analysis methods. *Eur J Nucl Med Mol Imaging*. 2015 Apr;42(5):725-32.
182. Landau SM, Fero A, Baker SL, Koeppe R, **Mintun M**, Chen K, Reiman EM, Jagust WJ. Measurement of longitudinal β -amyloid change with 18F-florbetapir PET and standardized uptake value ratios. *J Nucl Med*. 2015 Apr;56(4):567-74.
183. Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, Visser PJ; Amyloid Biomarker Study Group., Aalten P, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BN, Bibeau K, Blennow K, Brooks DJ, van Buchem MA, Camus V, Cavedo E, Chen K, Chételat G, Cohen AD, Drzezga A, Engelborghs S, Fagan AM, Fladby T, Fleisher AS, van der Flier WM, Ford L, Förster S, Fortea J, Foskett N, Frederiksen KS, Freund-Levi Y, Frisoni GB, Froelich L, Gabryelewicz T, Gill KD, Gkatzima O, Gómez-Tortosa E, Gordon MF, Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka SK, Hildebrandt H, Ishihara L, Ivanoiu A, Jagust WJ, Johannsen P, Kandimalla R, Kapaki E, Klimkowicz-Mrowiec A, Klunk WE, Köhler S, Koglin N, Kornhuber J, Kramberger MG, Van Laere K, Landau SM, Lee DY, de Leon M, Lisetti V, Lleó A, Madsen K, Maier W, Marcusson J, Mattsson N, de Mendonça A, Meulenbroek O, Meyer PT, **Mintun MA**, Mok V, Molinuevo JL, Møllergård HM, Morris JC, Mroczko B, Van der Mussele S, Na DL, Newberg A, Nordberg A, Nordlund A, Novak GP, Paraskevas GP, Parnetti L, Perera G, Peters O, Popp J, Prabhakar S, Rabinovici GD, Ramakers IH, Rami L, Resende de Oliveira C, Rinne JO, Rodrigue KM, Rodríguez-Rodríguez E, Roe CM, Rot U, Rowe CC, Rütther E, Sabri O, Sanchez-Juan P, Santana I, Sarazin M, Schröder J, Schütte C, Seo SW, Soetewey F, Soininen H, Spuru L, Struyfs H, Teunissen CE, Tsolaki M, Vandenberghe R, Verbeek MM, Villemagne VL, Vos SJ, van Waalwijk van Doorn LJ, Waldemar G, Wallin A, Wallin ÅK, Wiltfang J, Wolk DA, Zboch M, Zetterberg H. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. *JAMA*. 2015 May 19;313(19):1924-38.
184. Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BN, Scheltens P, Visser PJ; Amyloid PET Study Group, Verfaillie SC, Zwan MD, Adriaanse SM, Lammertsma AA, Barkhof F, Jagust WJ, Miller BL, Rosen HJ, Landau SM, Villemagne VL, Rowe CC, Lee DY, Na DL, Seo SW, Sarazin M, Roe CM, Sabri O, Barthel H, Koglin N, Hodges J, Leyton CE, Vandenberghe R, van Laere K, Drzezga A, Forster S, Grimmer T, Sánchez-Juan P, Carril JM, Mok V, Camus V, Klunk WE, Cohen AD, Meyer PT, Hellwig S, Newberg A, Frederiksen KS, Fleisher AS, **Mintun MA**, Wolk DA, Nordberg A, Rinne JO, Chételat G, Lleó A, Blesa R, Fortea J, Madsen K, Rodrigue KM, Brooks DJ. Prevalence of amyloid PET positivity in dementia Syndromes: a meta-analysis. *JAMA*. 2015 May 19; 313(19):1939-49.
185. Black KJ, Piccirillo ML, Koller JM, Hsieh T, Wang L, **Mintun MA**. Levodopa effects on [(11)C]raclopride binding in the resting human brain. *F1000Res*. 2015 Jan 23;4:23.
186. Joshi AD, Pontecorvo MJ, Lu M, Skovronsky DM, **Mintun MA**, Devous MD Sr. A Semiautomated Method for Quantification of F 18 Florbetapir PET Images. *J Nucl Med*. 2015 Nov;56(11):1736-41.

187. Coric V, Salloway S, van Dyck CH, Dubois B, Andreasen N, Brody M, Curtis C, Soininen H, Thein S, Shiovitz T, Pilcher G, Ferris S, Colby S, Kerselaers W, Dockens R, Soares H, Kaplita S, Luo F, Pachai C, Bracoud L, **Mintun M**, Grill JD, Marek K, Seibyl J, Cedarbaum JM, Albright C, Feldman HH, Berman RM. Targeting Prodromal Alzheimer Disease with Avagacestat: A Randomized Clinical Trial. *JAMA Neurol*. 2015 Nov 1;72(11):1324-33.
188. Grundman M, Johnson KA, Lu M, Siderowf A, Dell'Agnello G, Arora AK, Skovronsky DM, **Mintun MA**, Pontecorvo MJ; 18F-AV-45-A17 Study Group. Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria. *Dement Geriatr Cogn Disord*. 2016 Jan 8;41(1-2):80-92.
189. Schwarz AJ, Yu P, Miller BB, Shcherbinin S, Dickson J, Navitsky M, Joshi AD, Devous MD Sr, **Mintun MA**. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. *Brain*. 2016 May;139 (Pt 5):1539-50.
190. Shcherbinin S, Schwarz AJ, Joshi A, Navitsky M, Flitter M, Shankle WR, Devous MD Sr, **Mintun MA**. Kinetics of the Tau PET Tracer 18F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease. *J Nucl Med*. 2016 Oct;57(10):1535-1542.
191. Barret O, Alagille D, Sanabria S, Comley RA, Weimer RM, Borroni E, **Mintun M**, Seneca N, Papin C, Morley T, Marek K, Seibyl JP, Tamagnan GD, Jennings D. Kinetic modeling of the Tau PET Tracer 18F-AV-1451 in Human Healthy Volunteers and Alzheimer's disease Subjects. *J Nucl Med*. 2016 Dec 1.
192. Pontecorvo MJ, Arora AK, Devine M, Lu M, Galante N, Siderowf A, Devadanam C, Joshi AD, Heun SL, Teske BF, Trucchio SP, Krautkramer M, Devous MD Sr, **Mintun MA**. Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imaging. *Eur J Nucl Med Mol Imaging*. 2017 May 44(5):825-837
193. Pontecorvo MJ, Devous MD Sr, Navitsky M, Lu M, Salloway S, Schaerf FW, Jennings D, Arora AK, McGeehan A, Lim NC, Xiong H, Joshi AD, Siderowf A, **Mintun MA**. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. 18F-AV-1451-A05 investigators. *Brain*. 2017 Mar 1;140(3):748-763.
194. Tosun D, Landau S, Aisen PS, Petersen RC, **Mintun M**, Jagust W, Weiner MW; Alzheimer's Disease Neuroimaging Initiative. Association between tau deposition and antecedent amyloid- β accumulation rates in normal and early symptomatic individuals. *Brain*. 2017 May 1;140(5):1499-1512
195. Fleisher AS, Joshi AD, Sundell KL, Chen YF, Kollack-Walker S, Lu M, Chen S, Devous MD Sr, Seibyl J, Marek K, Siemers ER, **Mintun MA**. Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials. *Alzheimer's Dement*. 2017 Oct; 13(10):1117-1124.

196. Golla SS, Timmers T, Ossenkoppele R, Groot C, Verfaillie S, Scheltens P, van der Flier WM, Schwarte L, **Mintun MA**, Devous M, Schuit RC, Windhorst AD, Lammertsma AA, Boellaard R, van Berckel BN, Yaqub M. Quantification of Tau Load Using [¹⁸F] AV1451 PET. *Mol Imaging Biol.* 2017 Dec; 19(6):963-971.
197. Breault C, Piper J, Joshi AD, Pirozzi SD, Nelson AS, Lu M, Pontecorvo MJ, **Mintun MA**, Devous MD. Correlation between two methods of florbetapir PET quantitative analysis. *Am J Nucl Med Mol Imaging.* 2017 Jul 15;7(3):84-91.
198. Pontecorvo MJ, Siderowf A, Dubois B, Doraiswamy PM, Frisoni GB, Grundman M, Nobili F, Sadowsky CH, Salloway S, Arora AK, Chevrette A, Deberdt W, Dell'Agnello G, Flitter M, Galante N, Lowrey MJ, Lu M, McGeehan A, Devous MD Sr, **Mintun MA**. Effectiveness of Florbetapir PET Imaging in Changing Patient Management. *Dement Geriatr Cogn Disord.* 2017 Aug 5 ;44(3-4):129-143.
199. Jansen WJ, Ossenkoppele R, Tijms BM, Fagan AM, Hansson O, Klunk WE, van der Flier WM, Villemagne VL, Frisoni GB, Fleisher AS, Lleó A, **Mintun MA**, Wallin A, Engelborghs S, Na DL, Chetelat G; Molinuevo JL, Landau SM, Mattsson N, Kornhuber J, Sabri O, Rowe CC, Parnetti L, Popp J, Fladby T, Jagust WJ, Aalten P, Lee DY, Vandenberghe R, de Oliveira CR, Kapaki E, Froelich L, Ivanoiu A, Gabryelewicz T, Verbeek MM, Sanchez-Juan P, Hildebrandt H, Camus V, Zboch M, Brooks DJ, Drzezga A, Rinne JO, Newberg A, de Mendonça A, Sarazin M, Rabinovici GD, Madsen K, Rot U, Nordberg A, Mok V, Mroczko B, Wolk DA, Meyer PT, Tsolaki M, Amyloid Biomarker Study Group, Scheltens P, Verhey FRJ, Visser PJ. Association of Cerebral Amyloid- β Aggregation with Cognitive Functioning in Persons without Dementia. *JAMA Psychiatry.* 2018 Jan 1; 75(1):84-95.
200. Hou C, Hsieh CJ, Li S, Lee H, Graham TJ, Xu K, Weng CC, Doot RK, Chu W, Chakraborty SK, Dugan LL, **Mintun MA**, Mach RH. Development of a Positron Emission Tomography Radiotracer for Imaging Elevated Levels of Superoxide in Neuroinflammation. *ACS Chem Neurosci.* 2018 Mar 2; 9(3):578-586.
201. Southekal S, Devous MD Sr, Kennedy I, Navitsky M, Lu M, Joshi AD, Pontecorvo MJ, **Mintun MA**. Flortaucipir F 18 Quantitation Using Parametric Estimation of Reference Signal Intensity. *J Nucl Med.* 2018 Jun 59(6):944-951.
202. Devous MD Sr, Joshi AD, Navitsky M, Southekal S, Pontecorvo MJ, Shen H, Lu M, Shankle WR, Seibyl JP, Marek K, **Mintun MA**. Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18. *J Nucl Med.* 2018 Jun 59(6):937-943.
203. Navitsky M, Joshi AD, Kennedy I, Klunk WE, Rowe CC, Wong DF, Pontecorvo MJ, **Mintun MA**, Devous MD Sr. Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. *Alzheimers Dement.* 2018 Dec 14(12):1565-1571
204. Stern Robert A., Adler, Charles H., Chen, Kewei, Navitsky Michael, Luo Ji, Dodick David, Alosco Michael, Tripodis Yorghos, Goradia Dhruman, Martin Brett, Mastreni Diego, Fritts Nathan, Jarnagin Johnny, Devous MD Sr., **Mintun MA**, Pontecorvo MJ, Shenton Martha, Reiman Eric M. Tau Positron-Emission Tomography in Former

205. Pontecorvo MJ, Devous MD, Kennedy I, Navitsky M, Lu M, Galante N, Salloway S, Doraiswamy PM, Southehal S, Arora AK, McGeehan A, Lim NC, Xiong H, Trucchio SP, Joshi AD, Shcherbinin S, Teske B, Fleisher AS, **Mintun MA**. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia. *Brain*. 2019 Jun 1;142(6):1723-1735. doi: 10.1093/brain/awz090. PubMed PMID: 31009046; PubMed Central PMCID: PMC6536847.
206. Pontecorvo MJ, Keene CD, Beach TG, Montine TJ, Arora AK, Devous MD Sr, Navitsky M, Kennedy I, Joshi AD, Lu M, Serrano GE, Sue LI, Intorcchia AJ, Rose SE, Wilson A, Hellstern L, Coleman N, Flitter M, Aldea P, Fleisher AS, **Mintun MA**, Siderowf A. Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer's disease pathology: a clinicopathological study. *EJNMMI Res*. 2020 Jun 15;10(1):65. doi: 10.1186/s13550-020-00653-x.
207. Fleisher AS, Pontecorvo MJ, Devous MD Sr, Lu M, Arora AK, Trucchio SP, Aldea P, Flitter M, Locascio T, Devine M, Siderowf A, Beach TG, Montine TJ, Serrano GE, Curtis C, Perrin A, Salloway S, Daniel M, Wellman C, Joshi AD, Irwin DJ, Lowe VJ, Seeley WW, Ikonovic MD, Masdeu JC, Kennedy I, Harris T, Navitsky M, Southehal S, **Mintun MA**; A16 Study Investigators. Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. *JAMA Neurol*. 2020 Apr 27:e200528. doi: 10.1001/jamaneurol.2020.0528. Online ahead of print.
208. Pontecorvo MJ, Keene CD, Beach TG, Montine TJ, Arora AK, Devous MD Sr NavitskyM, Kennedy I, Joshi AD, Lu M, Serrano GE, Sue LI, Intorcchia AJ, Rose SE, Wilson A, Hellstern L, Coleman N, Flitter M, Aldea P, Fleisher AS, **Mintun MA**, Siderowf A. Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer's disease pathology: a clinicopathological study. *EJNMMI Res*. 2020 Jun 15;10(1):65. doi: 10.1186/s13550-020-00653-x. PMID: 32542468; PMCID: PMC7295920.
209. **Mintun MA**, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, Shcherbinin S, Sparks J, Sims JR, Brys M, Apostolova LG, Salloway SP, Skovronsky DM. Donanemab in Early Alzheimer's Disease. *N Engl J Med*. 2021 Mar 13. doi: 10.1056/NEJMoA2100708. Epub ahead of print. PMID: 33720637.
210. Lu M, Pontecorvo MJ, Devous MD Sr, Arora AK, Galante N, McGeehan A, Devadanam C, Salloway SP, Doraiswamy PM, Curtis C, Trucchio SP, Flitter M, Locascio T, Devine M, Zimmer JA, Fleisher AS, **Mintun MA**; AVID Collaborators. Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease: Results From 2 Phase III Clinical Trials. *JAMA Neurol*. 2021 Apr 1;78(4):445-453. doi: 10.1001/jamaneurol.2020.5505. PMID: 33587110; PMCID: PMC7885097.

211. Gupta HV, Beach TG, Mehta SH, Shill HA, Driver-Dunckley E, Sabbagh MN, Belden CM, Liebsack C, Dugger BN, Serrano GE, Sue LI, Siderowf A, Pontecorvo MJ, **Mintun MA**, Joshi AD, Adler CH. Clinicopathological Correlation: Dopamine and Amyloid PET Imaging with Neuropathology in Three Subjects Clinically Diagnosed with Alzheimer's Disease or Dementia with Lewy Bodies. *J Alzheimers Dis.* 2021;80(4):1603-1612. doi: 10.3233/JAD-200323. PMID: 33720879.

Reviews and Book Chapters

1. Herscovitch P, Gado M, **Mintun MA**, Raichle ME: The Necessity for Correcting for Cerebral Atrophy in Global Positron Emission Tomography Measurements. *Monogram Neural Sci* 1984; 11:93-97.
2. Raichle ME, Herscovitch P, **Mintun MA**, Martin RW. Cerebral Metabolism with Positron Emission Tomography and O-15 Radiopharmaceuticals. *Int J Neurol* 1984; 18:75-78.
3. Ter-Pogossian MM, Ficke DC, **Mintun MA**, Herscovitch P, Fox PT, Raichle ME: Dynamic Cerebral Positron Emission Tomographic Studies. *Ann Neurol* 1984; 15:S46-S47.
4. Raichle ME, **Mintun MA**, Herscovitch P. Positron Emission Tomography with O-15-Oxygen Radiopharmaceuticals. In: *Brain Imaging and Brain Function*, ed. Sokoloff: Raven Press (New York), 1985.
5. Raichle ME, Herscovitch P, **Mintun MA**, Martin WRW. Dynamic Measurements of Local Blood Flow and Metabolism in Man with Positron Tomography. In: *The Metabolism of the Human Brain Studied with Positron Emission Tomography*, eds. Greitz T, Ingvar DH, and Widen L; Raven Press (New York), 1985.
6. Powers WJ, **Mintun MA**. The role of Positron Emission Tomography in Identification of the Ischemic Penumbra. In: *Cerebrovascular Diseases, Fifteenth Research (Princeton) Conference*, eds. Powers WP and Raichle ME; Raven Press (New York), 1987.
7. Schuster DP, **Mintun MA**. Pulmonary Circulation, Extravascular Water, and Solute Flux as Determined by Positron Emission Tomography. *Lymphology* 1987; 20:25-35.
8. Schuster DP, **Mintun MA**. Studying the Pulmonary Circulation with Positron Emission Tomography. *J Thorac Img* 1988; 3:15-24.
9. **Mintun MA**, Siegel BA: Applications of Positron Emission Tomography. *J Crit Care* 1988; 3:1-4 (editorial).
10. Kuhl DE, Wagner HN, Alavi A, Coleman RE, Gould KL, Larson SM, **Mintun MA**, Siegel BA (ACNP/SNM Task Force on Clinical PET): Positron Emission Tomography (PET): Clinical Status in the United States in 1987. *J Nucl Med* 1988; 29:1136-1143.
11. Reiman EM, **Mintun MA**: Positron Emission Tomography. *Arch Intern Med* 1990; 150:729-731.
12. **Mintun MA**, McGuire AH, Welch MJ, Siegel BA, Katzenellenbogen JA: PET Imaging of Estrogen Receptors in Breast Cancer. In: *ACNP/University of Michigan/Department of*

Energy Joint Symposium on In vivo Imaging of Neurotransmitter Functions in Brain, Heart, and Tumors, eds. Kuhl DE; DOE, 1991;277-292.

13. Dobkin JA, **Mintun MA**: Clinical PET: Aesop's Tortoise? *Radiology* 1993; 186:13-15.
14. Diehl DJ and **Mintun MA**: Positron emission tomography: Basic principles and potential applications in the critically ill. In: *Textbook of Critical Care, 3rd Edition.*, eds. S.M. Ayres, A. Grenvik, P.R. Holbrook, and W.C. Shoemaker; W.B. Saunders (Philadelphia), 1995.
15. Townsend DW, Price JC, Lopresti B, **Mintun MA**, Kinahan PE, Jadali F, Sashin D, Simpson N and Mathis CA. Scatter correction in PET activation. In: *Quantification of Brain Function Using PET.* eds. R. Myers, T. Jones, D. Bailey; Academic Press (California), 1995; 16:76-81.
16. Price JC, Mathis CA, Simpson NR, Mahmood K, and **Mintun MA**. Kinetic Modeling of Serotonin-1A Binding in Monkeys Using [11C] WAY 100635 and PET. In: *Quantification of Brain Function Using PET.* eds. R. Myers, T. Jones, D. Bailey; Academic Press (California), 1996; 17:257-261.
17. Sheline, Y.I. and **Mintun M.A.** Structural and Functional Imaging Studies in Affective Disorders. In *Neuropsychopharmacology: Fifth Generation of Progress*, J. Coyle, D. Charney, K. Davis, C. Nemeroff (Eds), Raven Press, 2001.
18. Vlassenko AG, Makeyev SS, **Mintun MA**. Positron Emission Tomography in Neuro-oncology: Clinical Applications and Promising Strategies. *Ukrainian Journal of Neurosurgery* 2001; 15: 29-37.
19. Vlassenko AG, Makeyev SS, **Mintun MA**. Brain Positron Emission Tomography: Basic Principles and Applications in Humans. *Ukrainian Journal of Medicine* 2002; 28: 13-18.
20. **Mintun MA**. Utilizing advanced imaging and surrogate markers across the spectrum of Alzheimer's disease. *CNS Spectr.* 2005 Nov; 10 (11 Suppl 18); 13-6.